Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinomaChoueiri, Toni K ; Powles, Thomas ; Braun, David ; Fong, Lawrence ; George, Daniel ; Haas, Naomi ; McDermott, David F ; Shuch, Brian ; Gurney, Howard ; Meehan, Robert ; Posadas, Tracey ; Wu, Sterling ; Elfiky, Aymen ; Motzer, Robert JThe oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S15-S15 [Periódico revisado por pares]US: Oxford University PressTexto completo disponível |
|
2 |
Material Type: Artigo
|
19 Phase II Trial of Ubamatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid SarcomaMsaouel, PavlosThe oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S13-S14 [Periódico revisado por pares]US: Oxford University PressTexto completo disponível |
|
3 |
Material Type: Artigo
|
5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605McKay, Rana R ; Garmezy, Ben ; Barata, Pedro ; Ornstein, Moshe ; Shah, Neil J ; Hammers, Hans ; Hutson, Thomas E ; Chisamore, Michael ; Karim, Dhamina ; Mattson, Paulette ; Lightcap, Eric ; Drees, Jeremy ; Harrison, Ben ; Holm, Megan ; Bose, Nandita ; Thomas, Cherry T ; Motzer, Robert JThe oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S13-S13 [Periódico revisado por pares]US: Oxford University PressTexto completo disponível |
|
4 |
Material Type: Artigo
|
Advanced Renal Cell Cancer Combination Immunotherapy Clinical Trial (ARCITECT; HCRN GU 22-587)Serzan, MichaelThe oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S12-S13 [Periódico revisado por pares]US: Oxford University PressTexto completo disponível |
|
5 |
Material Type: Artigo
|
75 WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell CancerStewart, Professor Grant ; Jones, James ; Warren, Anne ; Gallagher, Professor Ferdia ; Menih, Ines Horvat ; Mossop, Helen ; Wason, Professor James ; Easita, Farhana ; Thomas, Martin ; Welsh, Sarah ; Mitchell, Mr Tom ; Ursprung, Stephan ; O’Carrigan, BrentThe oncologist (Dayton, Ohio), 2024-08, Vol.29 (Supplement_1), p.S15-S16 [Periódico revisado por pares]US: Oxford University PressTexto completo disponível |
|
6 |
Material Type: Artigo
|
29 Pilot study of an implantable microdevice forin vivo evaluation of drug response in renal cell carcinoma (NCT05700461)Xu, Wenxin ; Bhagavatula, Sharath ; Steiner, Clara ; Zhong, Caiwei ; Mossanen, Matthew ; Chang, Steven ; Hirsch, Michelle ; Ahn, Sebastian ; Matthew, Destiny ; Berg, Stephanie ; Serzan, Michael ; McGregor, Bradley ; Hata, Nobuhiko ; Viswanathan, Srinivas ; Silverman, Stuart ; Jonas, Oliver ; Choueiri, ToniThe oncologist (Dayton, Ohio), 2024-08, Vol.29 (Suppl 1), p.S14-S15 [Periódico revisado por pares]US: Oxford University PressTexto completo disponível |
|
7 |
Material Type: Artigo
|
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinomaMcDermott, David F ; Peer, Avivit ; Agarwal, Neeraj ; Atkins, Michael B ; Cornell, Jerry ; Perini, Rodolfo F ; Grossmann, Kenneth F ; Gurney, HowardThe oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S11-S11 [Periódico revisado por pares]US: Oxford University PressTexto completo disponível |
|
8 |
Material Type: Artigo
|
A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCCJonasch, Eric ; Hauke, Ralph ; Falchook, Gerald ; Logan, Theodore ; Gordon, Michael ; Hall, Evan ; Schuch, Brian ; Bilen, Mehmet A ; Naqash, Abdul ; Zakaharia, Yousef ; Ryan, Christopher W ; Lally, Satwant ; Xiao, Jim ; Zimmerman, Zachary ; Srinivasan, Ramaprasad ; Choueiri, Toni KThe oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S12-S12 [Periódico revisado por pares]US: Oxford University PressTexto completo disponível |
|
9 |
Material Type: Artigo
|
Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinomaBeckermann, Kathryn ; Rini, Brian ; Haas, Naomi ; George, Daniel ; Jonasch, EricThe oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S13-S14 [Periódico revisado por pares]US: Oxford University PressTexto completo disponível |
|
10 |
Material Type: Artigo
|
OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)Beckermann, Kathryn ; Haake, Scott ; Reddy, Anupama ; Shyr, Yu ; Kimryn Rathmell, W ; Pal, Sumanta ; Ornstein, Moshe ; Barata, Pedro ; Zhang, Tian ; Rini, BrianThe oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S14-S14 [Periódico revisado por pares]US: Oxford University PressTexto completo disponível |